Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in MDS-associated SAID
NCT02985190Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Jan 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), systemic autoimmune disease, chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Overall response rate of Myelodysplastic syndrome and systemic autoimmune and inflammatory diseases at 6 months. Started Jan 2017; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)systemic autoimmune diseasechronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02985190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985190.